Evidence map›Paper›PMID 34712435›Full record

ArticleMiddle East journal of digestive diseases2021

Effect of Baseline Resistance-Associated Substitutions on Thalassemia Patients with Chronic HCV Infection: A Two-Year Follow-Up.

Fahimeh Safarnezhad Tameshkel, Mohammad Hadi Karbalaie Niya, Mahmoodreza Khoonsari, Hossein Ajdarkosh, Amir Hossein Faraji, Mehdi Nikkhah, Nima Motamed, Azita Azarkeivan, Ali Gholami, Masood Reza Sohrabi and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Middle East journal of digestive diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Fahimeh Safarnezhad TameshkelGastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
Mohammad Hadi Karbalaie NiyaGastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
Mahmoodreza KhoonsariGastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
Hossein AjdarkoshGastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
Amir Hossein FarajiGastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
Mehdi NikkhahGastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
Nima MotamedDepartment of Social Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Azita AzarkeivanPediatric Hematology Oncology, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Thalassemia Clinic, Tehran, Iran.
Ali GholamiNon-communicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Masood Reza SohrabiGastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
Hossein KeyvaniGastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
Farhad ZamaniGastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
Iran University of Medical Sciences · IRHigh Institute for Education and Research in Transfusion Medicine · IRNon-Communicable Diseases Research CenterZanjan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Direct-acting antivirals (DAAs) against hepatitis C virus (HCV) infection showed the presence of resistant-associated substitutions (RASs). The aim of the present study was to carry out a follow-up of patients with baseline RASs to report the impact of RASs on DAA therapy outcome. METHODS In a cohort study, we analyzed NS5A and NS5B RASs among nine thalassemia cases by baseline RASs. In a 2-year follow-up, we analyzed viral markers and biochemical and hematological parameters of the participants and their sustained virologic response (SVR). Statistical analyses were performed using SPSS software version 22. RESULTS RASs for HCV subtype 1a included M28V, L31M, and H58P. For subtype 1b: L28M, R30Q, S24F, and C316N. And for subtype 3a: C316S, and S24F. In patients with cirrhosis (n = 5), ALT (

Indexed as

Chronic HCV infectionDirect acting antivirals (DAAs)Resistant associated substitutions (RASs)

Identifiers

PMID34712435
PMCPMC8531936
OpenAlexW3134478640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.